Selective BRAF inhibitors (BRAFis), such as vemurafenib, have been approved for clinical use and significantly improved the progression-free survival (PFS) and overall survival (OS) of patients with melanoma carrying BRAF mutations compared with the traditional chemotherapy dacarbazine (Chapman et al., 2011; Kim and Cohen, 2016; Chapman et al., 2017). Here, BRAF is linked to melanoma.